All In Biotech

Drug Trial Radar · NCT06031233

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapies; An Observational Prospective Study

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,082

Planned (sponsor's estimate)

Start

Sep 1, 2023

Primary completion

Jul 2028

Study completion Dec 2028

Sponsor

Lead sponsor
IsalaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.

Conditions

  • Oncology
  • Infusion Reaction

Interventions

  • NivolumabDrug

    Gradual shortening of infusion times

  • PembrolizumabDrug

    Gradual shortening of infusion times

  • IpilimumabDrug

    Gradual shortening of infusion times

  • DurvalumabDrug

    Gradual shortening of infusion times

  • AtezolizumabDrug

    Gradual shortening of infusion times

  • BevacizumabDrug

    Gradual shortening of infusion times

  • TrastuzumabDrug

    Gradual shortening of infusion times

  • RituximabDrug

    Gradual shortening of infusion times

  • InfliximabDrug

    Gradual shortening of infusion times

  • VedolizumabDrug

    Gradual shortening of infusion times

  • TociliuzumabDrug

    Gradual shortening of infusion times

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of infusion related reactionsTime frame: During or within 30 minutes after the end of the infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Isala Hospital

    Zwolle, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.